Accelerated Access to ALS and Neurodegenerative Disease Therapies
This act aims to speed up research and access to new drugs for individuals suffering from Amyotrophic Lateral Sclerosis (ALS) and other rare neurodegenerative diseases. Citizens may gain faster access to experimental therapies, as well as support for research into these conditions, potentially improving their quality of life and treatment prospects.
Key points
Financial support for research into new drugs for ALS and other rare neurodegenerative diseases.
Facilitating patient access to experimental drugs still in the research phase.
Establishing a public-private partnership to accelerate therapy development.
Developing an action plan by the Food and Drug Administration (FDA) for faster drug market entry.
Expired
Citizen Poll